Literature DB >> 9006004

Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3 analogs and 9-cis retinoic acid.

E Elstner1, M Linker-Israeli, J Le, T Umiel, P Michl, J W Said, L Binderup, J C Reed, H P Koeffler.   

Abstract

Patients with acute promyelocytic leukemia (APL) usually relapse after all-trans retinoic acid (RA) treatment because this therapy fails to eradicate the malignant clone. Our data showed that KH 1060 and other 20-epi vitamin D3 analogs alone were potent inhibitors of clonal growth of NB4 cells, an APL cell line (ED50, approximately 5 x 10(-11) M). The combination of KH 1060 and 9-cis-RA synergistically and irreversibly enhanced this effect. Neither KH 1060 nor 9-cis-RA (10(-6) M, 3 d) were strong inducers of differentiation of NB4 cells. However, 98% of the cells underwent differentiation to a mature phenotype with features of both granulocytes and monocytes after exposure to a combination of both compounds. Apoptosis only increased after incubation of NB4 cells with 9-cis-RA alone (28%) or with a combination of 9-cis-RA plus KH1060 (32%). Immunohistochemistry showed that the bcl-2 protein decreased from nearly 100% of the wild-type NB4 cells to 2% after incubation with a combination of KH 1060 and 9-cis-RA, and the bax protein increased from 50% of wild-type NB4 cells to 92% after culture with both analogs (5 x 10(-7) M, 3 d). Western blot analysis paralleled these results. Studies of APL cells from one untreated individual paralleled our results with NB4 cells. Taken together, the data demonstrated that nearly all of the NB4 cells can be irreversibly induced to differentiate terminally when exposed to the combination of KH 1060 and 9-cis-RA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9006004      PMCID: PMC507803          DOI: 10.1172/JCI119164

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  67 in total

1.  HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis.

Authors:  S J Martin; J G Bradley; T G Cotter
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

Review 2.  What is synergy?

Authors:  M C Berenbaum
Journal:  Pharmacol Rev       Date:  1989-06       Impact factor: 25.468

3.  Cloning and expression of full-length cDNA encoding human vitamin D receptor.

Authors:  A R Baker; D P McDonnell; M Hughes; T M Crisp; D J Mangelsdorf; M R Haussler; J W Pike; J Shine; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

4.  Expression of retinoic acid receptor genes and the ligand-binding selectivity of retinoic acid receptors (RAR's).

Authors:  Y Hashimoto; H Kagechika; K Shudo
Journal:  Biochem Biophys Res Commun       Date:  1990-02-14       Impact factor: 3.575

5.  Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells.

Authors:  E Elstner; M Linker-Israeli; T Umiel; J Le; I Grillier; J Said; I P Shintaku; S Krajewski; J C Reed; L Binderup; H P Koeffler
Journal:  Cancer Res       Date:  1996-08-01       Impact factor: 12.701

6.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells.

Authors:  D L Vaux; S Cory; J M Adams
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

7.  Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells.

Authors:  K Mehta; T McQueen; N Neamati; S Collins; M Andreeff
Journal:  Cell Growth Differ       Date:  1996-02

8.  Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia.

Authors:  A Raza; Y Maheshwari; H D Preisler
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

9.  bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation.

Authors:  T J McDonnell; N Deane; F M Platt; G Nunez; U Jaeger; J P McKearn; S J Korsmeyer
Journal:  Cell       Date:  1989-04-07       Impact factor: 41.582

10.  Differential expression and ligand regulation of the retinoic acid receptor alpha and beta genes.

Authors:  H de The; A Marchio; P Tiollais; A Dejean
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

View more
  6 in total

1.  Effects of vitamin D on the growth of normal and malignant B-cell progenitors.

Authors:  R Consolini; S Pala; A Legitimo; G Crimaldi; S Ferrari; S Ferrari
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

Review 2.  Effect of Vitamin D on Graft-versus-Host Disease.

Authors:  Alfonso Rodríguez-Gil; Estrella Carrillo-Cruz; Cristina Marrero-Cepeda; Guillermo Rodríguez; José A Pérez-Simón
Journal:  Biomedicines       Date:  2022-04-24

3.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.

Authors:  E Elstner; C Müller; K Koshizuka; E A Williamson; D Park; H Asou; P Shintaku; J W Said; D Heber; H P Koeffler
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

4.  Vitamin D in combination cancer treatment.

Authors:  Yingyu Ma; Donald L Trump; Candace S Johnson
Journal:  J Cancer       Date:  2010-07-15       Impact factor: 4.207

5.  Novel therapeutic approach: organic arsenical melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo.

Authors:  K Koshiuka; E Elstner; E Williamson; J W Said; Y Tada; H P Koeffler
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

Review 6.  Perspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin d and vitamin d analogs.

Authors:  Aleksandra Marchwicka; Małgorzata Cebrat; Preetha Sampath; Lukasz Snieżewski; Ewa Marcinkowska
Journal:  Front Oncol       Date:  2014-05-27       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.